Kaleido Biosciences (NASDAQ:KLDO) Rating Increased to Hold at Zacks Investment Research

Kaleido Biosciences (NASDAQ:KLDO) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Friday, Zacks.com reports.

According to Zacks, “Kaleido Biosciences Inc. is a clinical-stage healthcare company. It focuses on leveraging the potential of the microbiome organ to treat disease and improve human health. The Company’s product candidates are Microbiome Metabolic Therapies(TM), which are designed to modulate the metabolic output and profile of the microbiome by driving the function and distribution of the organ’s existing microbes. Kaleido Biosciences Inc. is based in Lexington, Massachusetts. “

KLDO has been the topic of several other reports. JPMorgan Chase & Co. initiated coverage on Kaleido Biosciences in a research report on Monday, March 25th. They set a “neutral” rating and a $15.00 price target on the stock. Morgan Stanley initiated coverage on Kaleido Biosciences in a research report on Monday, March 25th. They set an “overweight” rating and a $17.00 price target on the stock. Canaccord Genuity initiated coverage on Kaleido Biosciences in a research report on Monday, March 25th. They set a “buy” rating and a $19.00 price target on the stock. Chardan Capital initiated coverage on Kaleido Biosciences in a research report on Tuesday, April 23rd. They set a “buy” rating and a $17.50 price target on the stock. Finally, Goldman Sachs Group initiated coverage on Kaleido Biosciences in a research report on Monday, March 25th. They set a “buy” rating and a $20.00 price target on the stock. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Kaleido Biosciences has a consensus rating of “Buy” and a consensus target price of $17.70.

Shares of KLDO opened at $14.26 on Friday. Kaleido Biosciences has a fifty-two week low of $12.50 and a fifty-two week high of $19.00.

Kaleido Biosciences (NASDAQ:KLDO) last announced its quarterly earnings results on Thursday, May 2nd. The company reported ($1.56) earnings per share for the quarter, missing the consensus estimate of ($0.67) by ($0.89). As a group, analysts anticipate that Kaleido Biosciences will post -2.78 earnings per share for the current year.

Several large investors have recently bought and sold shares of KLDO. FMR LLC acquired a new stake in shares of Kaleido Biosciences during the 1st quarter valued at about $25,143,000. Baillie Gifford & Co. acquired a new stake in shares of Kaleido Biosciences during the 1st quarter valued at about $6,380,000. Victory Capital Management Inc. acquired a new stake in shares of Kaleido Biosciences during the 1st quarter valued at about $1,390,000. Arrowgrass Capital Partners US LP acquired a new stake in shares of Kaleido Biosciences during the 1st quarter valued at about $725,000. Finally, Dean Capital Investments Management LLC acquired a new stake in shares of Kaleido Biosciences during the 1st quarter valued at about $611,000. Hedge funds and other institutional investors own 77.83% of the company’s stock.

Kaleido Biosciences Company Profile

Kaleido BioSciences, Inc develops microbiome metabolic therapies. It offers treatment for hyperammonemia, a metabolic condition generally characterized by elevated levels of ammonia in the blood; infections caused by multi-drug resistant bacteria; chronic kidney disease; atherosclerotic cardiovascular disease; and drug or disease induced diarrhea.

Featured Article: Recession

Get a free copy of the Zacks research report on Kaleido Biosciences (KLDO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Kaleido Biosciences (NASDAQ:KLDO)

Receive News & Ratings for Kaleido Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kaleido Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.